Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lean-donor fecal phage transplantation in metabolic syndrome
NL-OMON48768Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised trial in insulin resistance (IR) and cardiometabolic risk (CMR) comparing Placebo with Fecal filtrate transplant (2 arms). Primary endpoints: Glucose tolerance, HbA1c and 3 more. Started Jul 2019; status: active, not recruiting.
02
Drugs
fecal filtrate transplant
03
Conditions
insulin resistance (IR)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on NL-OMON48768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48768.